Veracyte, Inc. (NASDAQ:VCYT) Just Released Its Annual Results And Analysts Are Updating Their Estimates
Veracyte, Inc. (NASDAQ:VCYT) Just Released Its Annual Results And Analysts Are Updating Their Estimates
It's been a sad week for Veracyte, Inc. (NASDAQ:VCYT), who've watched their investment drop 10% to US$22.18 in the week since the company reported its full-year result. It was a pretty bad result overall; while revenues were in line with expectations at US$361m, statutory losses exploded to US$1.02 per share. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. So we collected the latest post-earnings statutory consensus estimates to see what could be in store for next year.
對於Veracyte, Inc.(納斯達克股票代碼:VCYT)來說,這是悲慘的一週,自該公司公佈全年業績以來,他們的投資下降了10%,至22.18美元。總體而言,這是一個相當糟糕的業績;雖然收入符合預期,爲3.61億美元,但法定虧損激增至每股1.02美元。根據結果,分析師更新了他們的盈利模式,很高興知道他們是否認爲公司的前景發生了巨大變化,或者業務是否照舊。因此,我們收集了最新的業績後法定共識估計,以了解明年可能會發生什麼。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240224/0-4cdb5048885d52a6d89972142930051a-0-3ecb22573c41a1f8b5d93326cfaa0d48.png/big)
Taking into account the latest results, the current consensus from Veracyte's nine analysts is for revenues of US$395.6m in 2024. This would reflect a notable 9.6% increase on its revenue over the past 12 months. The loss per share is expected to greatly reduce in the near future, narrowing 76% to US$0.24. Before this latest report, the consensus had been expecting revenues of US$393.2m and US$0.26 per share in losses. It looks like there's been a modest increase in sentiment in the recent updates, with the analysts becoming a bit more optimistic in their predictions for losses per share, even though the revenue numbers were unchanged.
考慮到最新業績,Veracyte的九位分析師目前的共識是,2024年的收入爲3.956億美元。這將反映其收入在過去12個月中顯著增長9.6%。預計每股虧損將在不久的將來大幅減少,縮小76%至0.24美元。在這份最新報告之前,共識一直預計收入爲3.932億美元,每股虧損0.26美元。在最近的更新中,市場情緒似乎略有增加,儘管收入數字保持不變,但分析師對每股虧損的預測卻變得更加樂觀了。
The average price target held steady at US$31.67, seeming to indicate that business is performing in line with expectations. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. Currently, the most bullish analyst values Veracyte at US$37.00 per share, while the most bearish prices it at US$22.00. As you can see, analysts are not all in agreement on the stock's future, but the range of estimates is still reasonably narrow, which could suggest that the outcome is not totally unpredictable.
平均目標股價穩定在31.67美元,這似乎表明業務表現符合預期。但是,固定單一價格目標可能是不明智的,因爲共識目標實際上是分析師目標股價的平均值。因此,一些投資者喜歡查看估計範圍,看看對公司的估值是否有任何分歧。目前,最看漲的分析師對Veracyte的估值爲每股37.00美元,而最看跌的分析師估值爲22.00美元。如你所見,分析師對該股的未來並不完全一致,但估計範圍仍然相當狹窄,這可能表明結果並非完全不可預測。
Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. It's pretty clear that there is an expectation that Veracyte's revenue growth will slow down substantially, with revenues to the end of 2024 expected to display 9.6% growth on an annualised basis. This is compared to a historical growth rate of 29% over the past five years. Compare this against other companies (with analyst forecasts) in the industry, which are in aggregate expected to see revenue growth of 17% annually. So it's pretty clear that, while revenue growth is expected to slow down, the wider industry is also expected to grow faster than Veracyte.
現在從大局來看,我們理解這些預測的方法之一是了解它們與過去的業績和行業增長估計相比如何。很明顯,預計Veracyte的收入增長將大幅放緩,預計到2024年底的收入按年計算將增長9.6%。相比之下,過去五年的歷史增長率爲29%。相比之下,該行業的其他公司(根據分析師的預測),後者的總體收入預計每年將增長17%。因此,很明顯,儘管收入增長預計將放緩,但整個行業的增長速度預計也將超過Veracyte。
The Bottom Line
底線
The most obvious conclusion is that the analysts made no changes to their forecasts for a loss next year. Fortunately, the analysts also reconfirmed their revenue estimates, suggesting that it's tracking in line with expectations. Although our data does suggest that Veracyte's revenue is expected to perform worse than the wider industry. The consensus price target held steady at US$31.67, with the latest estimates not enough to have an impact on their price targets.
最明顯的結論是,分析師對明年虧損的預測沒有改變。幸運的是,分析師還重申了他們的收入預期,表明收入符合預期。儘管我們的數據確實表明,預計Veracyte的收入表現將比整個行業差。共識目標股價穩定在31.67美元,最新估計不足以對其目標價格產生影響。
With that said, the long-term trajectory of the company's earnings is a lot more important than next year. At Simply Wall St, we have a full range of analyst estimates for Veracyte going out to 2026, and you can see them free on our platform here..
話雖如此,公司收益的長期軌跡比明年重要得多。在Simply Wall St,我們有分析師對Veracyte到2026年的全方位估計,你可以在我們的平台上免費看到這些估計。
Before you take the next step you should know about the 2 warning signs for Veracyte (1 is concerning!) that we have uncovered.
在你採取下一步行動之前,你應該了解 Veracyte 的 2 個警告信號(1 個令人擔憂!)這是我們發現的。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。